Novo's diabetes drug “Ozempic” shows a relationship with reduced risk of dementia

2024/7/12 19:59 JST (some excerpts)

Research at Oxford University in England showed that the diabetes drug “Ozempic” from the Danish pharmaceutical company Novo Nordisk is related to a decrease in the incidence of symptoms such as dementia. The results raised expectations about the side effects of Ozempic.
　　According to the same study, patients who took Ozempic for 1 year had a 48% lower risk of dementia compared to patients who had taken sitagliptin before, and the risk of causing cognitive impairment was lower than patients taking sitagliptin or similarly previous glipizide.